Mid Cap

$1 Billion to $10 Billion

ARTICLES

This stock is in limbo, but there are two paths to significant gains for shareholders.

Purchase Recommendation - March 2018

While an investment in this mid-cap insurer carries significant, speculative risks, we believe that the upside potential justifies these risks. On the one hand, there is a determined buyer working toward completing a cash deal worth 90% more than the current share price. On the other hand, if the deal fails to pass regulatory muster, the company is currently valued at a remarkably low 11% of book value and 2x earnings, even as the underlying businesses appear to be improving.
Read More

Purchase Recommendation - September 2018

This month's purchase recommendation is a company that has grown by acquisitions that have then not been integrated well. The shares have declined sharply in the past three years. With several new board members (including one backed by an activist) and new company leadership, the company is starting to unlock the substantial value trapped in its asset base and improve its operating margins. With the company’s high debt level, its shares are not without risk. However, the catalysts plus a favorable secular tailwind give the shares more than enough upside to offset the risks.
Read More
This stock is in limbo, but there are two paths to significant gains for shareholders.

Purchase Recommendation - March 2018

While an investment in this mid-cap insurer carries significant, speculative risks, we believe that the upside potential justifies these risks. On the one hand, there is a determined buyer working toward completing a cash deal worth 90% more than the current share price. On the other hand, if the deal fails to pass regulatory muster, the company is currently valued at a remarkably low 11% of book value and 2x earnings, even as the underlying businesses appear to be improving.
Read More

Chesapeake Energy 4Q17 Results: A Step Forward

After reporting 4Q17 results, Chesapeake shares surged 22% on significantly improved EBITDA, driven by higher energy prices and lower operating costs. The cost improvement is a critical and highly encouraging part of our thesis. Chesapeake's previously scrambled operations now appear more focused and streamlined. We expect more progress in 2018.
Read More

Conduent 4Q17 Results--Making Clear Progress

In its first year as an independent company following its spin-off from Xerox, technology services firm Conduent (NYSE: CNDT) is making clear progress on improving its operating profitability and generating cash. Conduent is transitioning along the path that management outlined a year ago. We expect continued progress in 2018.
Read More

Allscripts 4Q17: Progressing Along

The turnaround for electronic health records firm Allscripts (Nasdaq: MDRX) continues along under CEO Paul Black, but progress is a bit slower than we like, somewhat lumpy, and distorted by the company's complex revenue and profit accounting.
Read More

Free Turnaround Letter Research Report: Bioverativ (NYSE: BIVV)

We're sharing this complimentary copy of our full Research Report for Bioverativ (NYSE: BIVV)—20+ pages of financial analysis, investment philosophy and straightforward explanation. BIVV, our most recent closed out purchase recommendation, brought Turnaround Letter readers 95% stock profit in seven short months.
Read More

Identify & Profit from Distressed Investing

Free Report: Turnaround Investing Mistakes

Turnaround Investing Blog

Turnaround Investing Blog

Books we Recommend for the Holidays

Looking for a stocking-stuffer for the investor or businessperson in your life, or perhaps for yourself? Don’t have a lot of time to stroll through a brick-n-mortar bookstore or wonder which books among Amazon’s endless inventory are actually worth buying? Our list, assembled by George Putnam and Bruce Kaser, includes some fascinating new titles as well as several timeless classics about successful investing and leadership. All are valuable reads which any recipient will be thrilled to dive into. Read More.

EV/EBITDA: What Is It & Why Are We Using It More?

In reading recent editions of The Turnaround Letter, you have probably noticed that we are increasingly using EV/EBITDA as a valuation measure, rather than the better-known price/earnings multiple.  We thought it might be useful to describe this measure and why we like it.

Read More.

Turnaround Letter Stock Pick Named Top Performer of 2017

 

stock market advicex

 

What Last Year's Top Stock Pickers Are Buying in 2018

 

This Forbes write-up follows up on the recent Top Stock Tips report--naming The Turnaround Letter's Crocs recommendation the top performer of 2017: With 90% gains, CROX beat out 100 other investment ideas included in the report; and the stock continues to have value investing appeal, according to Putnam.

 

George notes, "We see additional upside for the stock in 2018 as management's efforts continue to bear fruit, though the gains will likely be more muted than we saw in 2017."